Figure S3 shows representative stainings of (+), (++) or (+++) AKT2 expression in SCCs and ADCs. Tumours were classified into a low expression group comprising (−) and (+) and a high expression group that comprises (++) and (+++). AKT2 was overexpressed in 18/83 NSCLCs (∼22%) (Figure 3). At difference with AKT1, AKT2 overexpression was observed more frequently in SCCs (10/31 SCCs, 32%; 4/33 ADCs, 12%). See Figure 3A and B, respectively. In addition, most AKT2 positive tumours (12/17, 71%) showed AKT activation (Table 3). This evidence concerns the gene AKT2 and neoplasm.